In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase 3 EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups.

Key topics include

• Identifying tumors that remain endocrine-sensitive despite acquired resistance to previous ET

• Clinical implications of the EMERALD post-hoc subgroup analyses

• Review of elacestrant's safety profile

Clinical takeaways

• Duration of prior ET + CDK4/6i ≥12 months was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC endocrine monotherapy in patients with ESR1-mut, ER+/HER2– metastatic breast cancer

• The PFS benefit associated with elacestrant was consistent across clinically relevant subgroups evaluated, including patients with bone metastases, liver and/or lung metastases, n<3 or ≥3 metastatic sites or tumors with PIK3CA-mut, TP53-mut, HER2-low tumor expression, or ESR1-mut variants D538G or Y537S/N

• Safety analyses demonstrated that elacestrant had a manageable safety profile similar to other ETs and without evidence of the toxicities associated with other drug classes, such as CDK4/6i and PI3K/AKT/mTOR inhibitors

• These data support current guidelines that recommend routine testing for the emergence of ESR1-mut in ctDNA at each disease progression

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.

This video was developed by https://cor2ed.com/

Published March 2025

This podcast explores the best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer.

Dr Rena Callahan and Dr Roberto Salgado discuss key biomarkers, testing methods, and clinical decision-making, offering expert insights on how to optimise precision medicine.

Topics include liquid vs. tumour biopsy, single gene vs. broad panel testing, and regional differences in testing practices.

Tune in for a practical, expert-led discussion on how molecular testing can guide personalised treatment and improve patient outcomes.

Key clinical takeaways:

• Molecular testing, especially for biomarkers like ESR1 and PI3 kinase, is a critical component in guiding treatment decisions, particularly in second-line therapy for HR+ HER2- metastatic breast cancer.

• Liquid biopsy is a valuable tool for ongoing monitoring of metastasis and detecting mutations like ESR1 during disease progression, but tissue biopsies may yield more reliable results for certain mutations like PI3 kinase alterations present early in cancer development.

• Testing for a broad range of mutations, such as PI3 kinase, AKT, PTEN, ESR1, MSI, and NTRK, allows for the identification of actionable mutations and eligibility for newer targeted therapies, especially in second and third-line treatments.

• Clinicians must be familiar with the specifics of the assays used to test for mutations, as different methods and testing conditions can impact results.

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/precision-oncology-connect/programmes/molecular-testing-targeted-therapy-metastatic-breast-cancer/?media=0

Or watch on YouTube: https://www.youtube.com/watch?v=CTnXmh1oDwQ

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/ntrk-connect/

X: https://x.com/PresOnc_Connect

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Thermo Fisher Scientific.

This podcast is developed by cor2ed.com

Published March 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions

Key clinical takeaways:

• MMR status should be tested in all patients at diagnosis and upon disease progression to guide personalised treatment decisions

• ICI and ChT combination, including with maintenance olaparib, demonstrates benefits in patients with non-dMMR advanced/recurrent endometrial cancer, with greater efficacy observed in dMMR populations

• Lenvatinib plus pembrolizumab is a viable option not only as 2nd line therapy but also as 1st line treatment for patients with non-dMMR advanced/recurrent endometrial cancer who have progressed after prior systemic therapy in any setting

• Shared decision-making, supported by patient education, is essential for optimising treatment outcomes

The treatment landscape for advanced and recurrent endometrial cancer (EC) is evolving, with molecular classification playing a key role in guiding decisions. In this podcast, Prof. Xavier Matias-Guiu (Pathologist) and Dr Jurjees Hasan (Medical Oncologist) discuss the latest advancements in personalised treatment approaches for EC.

Key topics include:

• The role of molecular classification in guiding treatment selection and testing strategies

• Treatment options for patients with pMMR status

• Effective patient communication for shared decision-making

Tune in for expert insights and practical guidance to optimise treatment strategies in advanced and recurrent EC

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/obstetrics-gynecology-connect/programmes/endometrial-cancer-molecular-classification-treatment-decisions/

Or watch on YouTube: https://youtu.be/KvYIB7PBpyQ

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/ob-gyn-connect/?viewAsMember=true

X: https://x.com/OBGynConnect

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this podcast.

This podcast is developed by cor2ed.com

Published February 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Intermediate HCC – The evolving role of IO

In this final episode of the four-part series on hepatocellular carcinoma (HCC), hosted by the Oncology Brothers Drs Rohit and Rahul Gosain, the discussion focuses on the evolving role of immunotherapy (IO) in intermediate HCC. The episode explores multimodal approaches that combine IO and IO-based therapies with loco-regional treatments and highlights the essential role of a multidisciplinary care team.

Joined by Drs Nina Sanford (radiation oncologist), Mark Yarchoan (medical oncologist) and Ed Kim (interventional radiologist), the experts provide a brief overview of current treatment options for intermediate HCC, addressing its heterogeneity and standard treatment pathways. They delve into the latest clinical trial data (EMERALD-1, LEAP-012) on combining IO with loco-regional therapies, discussing clinical implications. The conversation also underscores the importance of effective collaboration within the multidisciplinary team for delivering optimal patient care. The episode concludes with future perspectives in the field and key clinical takeaways on integrating IO with loco-regional therapy and the significance of multidisciplinary care in managing HCC.

Key clinical takeaways:

• IO and IO-based treatments are moving earlier in the treatment paradigm for patients with intermediate HCC. Earlier integration of these therapies aims to achieve improved systemic control, allowing loco-regional therapy to target oligoprogression, residual lesions or reduce tumour burden

• Emerging data supports combining systemic and loco-regional therapies for patients with intermediate HCC. EMERALD-1 and LEAP-012 show promising PFS data using IO-based combination regimens like durvalumab + bevacizumab or pembrolizumab + lenvatinib alongside TACE. Long-term OS data are awaited

• Effective communication and coordinated care among specialists, such as medical oncologists, radiation oncologists, hepatologists, and interventional radiologists, are essential to developing optimal treatment strategies for patients with intermediate HCC

You can also watch a video of the experts in conversation and download the accompanying slides and transcript on our website: https://cor2ed.com/hcc-connect/programmes/intermediate-hcc-the-evolving-role-of-io/

Or watch on YouTube: https://www.youtube.com/watch?v=3voWa0U96lE

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/hcc-connect/

X https://x.com/hccconnectinfo

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. AstraZeneca has provided a sponsorship grant towards this independent programme.

This podcast is developed by cor2ed.com

Published on January 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. <...

In the third of this 4-part podcast series on HCC, the Oncology Brothers Dr Rahul and Dr Rohit Gosain are joined by Hepatologist Dr Maria Reig and Interventional Radiologist Dr Emil Cohen to explore the complexities of managing intermediate-stage hepatocellular carcinoma (HCC). Together, they unpack treatment options and strategies through a dynamic and engaging discussion rooted in real-world clinical practice.

Key topics include:

• An overview of the available treatment options for this heterogeneous patient population with intermediate HCC

• A deep dive into loco-regional therapies, including TACE, TARE (Y-90), and SBRT

• Exploring the role of systemic treatments in patients with intermediate HCC and the use of multimodal treatment approaches, combining loco-regional treatment options with systemic treatments

• The importance of the multidisciplinary care team for the treatment of intermediate HCC

Key clinical takeaways:

• Defined by guidelines, treatment options for patients with intermediate HCC include liver transplantation, loco-regional therapies, and systemic therapy. Treatment selection depends not only on tumour burden and liver function, but also on practical considerations in clinical practice

• Systemic therapies are being evaluated earlier in the disease course, particularly for intermediate HCC, either as standalone treatments or in combination with loco-regional therapies

• Ongoing clinical trials, such as REPLACE and ABC-HCC, aim to clarify the role of systemic therapies in intermediate HCC as standalone options, while others, like EMERALD-1 and LEAP-012, focus on their use in combination with loco-regional approaches

• Adverse events require identification of the specific adverse events profile. Regardless of origin (systemic or loco-regional), complications must be resolved to maintain treatment efficacy and ensure patient safety

• Optimal care for intermediate HCC relies on a multi-disciplinary team, including hepatologists, interventional radiologists, radiation oncologists, surgeons, and medical oncologists

Prefer to watch the experts in conversation? Go to the video on our website: https://cor2ed.com/hcc-connect/programmes/advanced-hcc-treatment-selection/

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/hcc-connect

X: https://x.com/hccconnectinfo

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.

This podcast is developed by cor2ed.com

Published January 2024

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Join the Oncology Brothers, Drs Rahul and Rohit Gosain, as they host an insightful discussion with Dr Lorenza Rimassa and Prof. Arndt Vogel. In the second of a 4-part podcast series, this episode dives into 2nd line treatment selection in advanced HCC and the key considerations for deciding when to switch therapies.

Topics include:

• 2nd line options for advanced HCC after 1st line TKIs and IO-based therapies

• Sequencing strategies and clinical practice approaches

• Key data supporting 2nd line decisions

• Factors to consider when transitioning to 2nd line therapy

Key clinical takeaways:

• Prospective Phase 3 data on 2nd line options in advanced HCC, particularly after immunotherapy, is limited, highlighting the need for further evidence to guide optimal treatment decisions

• When switching to 2nd line therapy, it is essential to evaluate all the available treatment options to ensure the optimal choice for each patient, considering efficacy, tolerability, liver function, and quality of life.

• Switching to 2nd line therapy should be considered in cases of clear disease progression, such as the appearance of new lesions outside the liver. Best supportive care should also be considered

• Managing side effects of 2nd line treatments (e.g. hypertension, skin toxicity, proteinuria) is critical for maintaining quality of life and providing optimal disease management

• Effective management requires a multidisciplinary team effort, including oncologists, hepatologists, interventional radiologists, and other specialists to optimise outcomes and proactively manage symptoms like hepatic decompensation

Prefer to watch the experts in conversation? Go to the video on our website: https://cor2ed.com/hcc-connect/programmes/advanced-hcc-treatment-selection/

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/hcc-connect

X: https://x.com/hccconnectinfo

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.

This podcast is developed by cor2ed.com

Published December 2024

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Testing to treatment of BRAF-mutant metastatic NSCLC

In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of BRAF mutations in metastatic non-small cell lung cancer (NSCLC), the testing strategies and first- and second-line treatment options for these patients.

The discussion focuses on which BRAF mutations to test for and when in the patient journey to test, before moving on to consider if NGS broad panel testing should be applied routinely for patients. Various treatments are considered, along with which decision criteria come into play when selecting a particular treatment.

The experts also discuss how to treat patients who have co-mutations detected during testing.

This is an informative podcast that culminates in some interesting key messages from two well-recognised Experts in the field of NSCLC.

Key clinical takeaways:

• Test all patients irrespective of histology and smoking history

• Test upfront so that more efficacious agents can be used earlier in the patient journey

• Next-generation sequencing is the gold-standard for testing wherever possible to ensure various targetable alterations are not missed

• There are effective BRAF + MEK inhibitor combination treatments available to treat our BRAFv600E-mutant metastatic NSCLC patients which have manageable safety profiles

Would you prefer to watch the experts in conversation? This podcast episode is also available in video format, here: https://youtu.be/UZPBUAFOwcY

Download the trasncript and find out more about this programme and the featured experts here: https://cor2ed.com/lung-connect/programmes/testing-treatment-braf-mutant-metastatic-nsclc/

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/lungconnect/

X: https://x.com/lung_connect

This content is intended for healthcare professionals outside of the UK & ROI only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.

This podcast is developed by https://cor2ed.com/

Published November 2024

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

In the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the use of IO (immunotherapy) in unresectable HCC (uHCC) and take a deep dive into the different treatment options first-line focusing on IO and IO based combinations. Topics include:

• Current first-line systemic treatment options for uHCC
• Efficacy and safety of IO and IO combinations including practical aspects of identifying and managing immune-mediated AEs
• How to select between the two first-line IO-based treatment options based on clinical factors and practical considerations

Key clinical takeaways:

• Two first-line IO and IO-based combinations are approved for patients with unresectable hepatocellular carcinoma (HCC), with ongoing advancements shaping the treatment landscape
• Clinical trials in newly diagnosed unresectable HCC patients have validated the effectiveness of IO plus anti-VEGF (atezolizumab + bevacizumab, IMbrave150) and dual IO (tremelimumab + durvalumab, HIMALAYA) approaches, establishing the proof of principle for these strategies
• Landmark analysis is critical in IO-based treatments due to the delayed and continued separation of survival curves. Notably, the STRIDE regimen ( single tremelimumab regular interval durvalumab) shows one in five patients achieving five-year survival in long-term follow-up
• IO and IO-based regimens for unresectable HCC are generally well-tolerated, with immune-related adverse effects manageable using steroids when necessary.
• In clinical practice, treatment choice should be individualized, taking into account factors such as potential side effects and logistical considerations, including the frequency of hospital visits

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/hcc-connect

X: https://x.com/hccconnectinfo

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. AstraZeneca has provided a sponsorship grant towards this independent programme.

This podcast is developed by cor2ed.com

Published on November 2024

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.